Skip to main content
OpenTrials
Completed

NCT Number: NCT04474392

Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins

The study is designed to learn more about the causes of rheumatoid arthritis (RA). People who get RA have elevated protein markers called autoantibodies in their blood years before initial symptoms of arthritis. The goal of this study is to learn more about how autoantibodies in RA might be related to inflammation in the lungs.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Colorado Denver (Anschutz Medical Campus)

Aurora, Colorado, 80045, United States

About this study

The Specific Aims of This Study Are As Follows:

  • Identify whether sputum anti-CCP predicts incident RA
  • Determine the effect of inflammatory cytokines on the induction of NETosis in sputum neutrophils
  • Determine the role of sputum macrophage phagocytosis in NET clearance <br> The knowledge gained from this study will improve the overall understanding of the development of RA. It is anticipated that these findings will improve the field's understanding of how best to screen for RA risk and target RA prevention. This study could support future lung-targeted prevention strategies for RA that could avoid the administration of systemic toxic therapies. Such potential prevention interventions could be implemented in subjects at risk for RA in order to prevent the irreversible joint damage that can occur in the later stages of clinically-apparent RA.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults between 18 and 100 years;
  • At-Risk for RA, RA diagnosed, and Healthy Control subjects will be included in the study until recruitment goals are met for each group.

At-Risk:

  • No evidence of inflammatory arthritis on clinical examination AND
  • At elevated risk for RA based on familial or serologic risk
  • Familial risk includes having a first degree relatives (FDRs) with RA
  • Serologic risk includes asymptomatic serum ACPA positivity

Healthy Controls :

  • No history of RA
  • No FDRs with RA
  • No systemic use of immunosuppressants for autoimmune disease

RA Diagnosis:

  • Classified RA by 1987 ACR and/or 2010 ACR/EULAR RA classification criteria (confirmed by medical chart review) OR
  • Diagnosed with RA by a board-certified rheumatologist (confirmed by medical chart review)

Exclusion criteria

  • Currently pregnant or planning to become pregnant during the sample collection period of the study
  • Exacerbation of underlying obstructive lung disease within the past 1 month
  • Known FEV1 <1 liter
  • Oxygen requirement >2 liters at rest
  • Participants with health acuity or behavioral health concerns leaving them unable to participate in the current research

Note: If a subject temporarily does not meet inclusion criteria but is interested in participating, he/she may participate once inclusion criteria have been met.

If interested, please take a few minutes to complete the screening questionnaire for this study opportunity. You may open the survey in your web browser by clicking the link below:

https://is.gd/SPAROscreen

If the link above does not work, try copying the link below into your web browser:

https://redcap.ucdenver.edu/surveys/?s=3WM8WH3WKK

Treatment and study plan

N/A (Observational Study)

Other

Observational study, no intervention will be administered.

Primary outcomes

  1. Sputum anti-CCP antibodies predicting incident RA

    Time frame: 1-3 years per participant (depending on group); study visits x1 per year, with option for 3 additional visits over 1 year for a subgroup of participants.

    *Sputum anti-CCP antibodies every year for 3 years (subjects At-Risk for RA); to identify whether sputum anti-CCP predicts incident RA

Secondary outcomes

  1. Effect of inflammatory cytokines on the induction of NETosis in sputum neutrophils

    Time frame: 1-3 yrs / participant; At-Risk Group: Baseline Visit & 2 Follow-up Annual Visits (w/ potential to have 3 additional visits in 1 year); Healthy Controls & RA Diagnosed: Baseline Visit & 1 Follow-up Visit, approximately 1 year later

    *Determine the effect of inflammatory cytokines on the induction of NETosis in sputum neutrophils

  2. The role of sputum macrophage phagocytosis in NET clearance

    Time frame: 1-3 years / participant; At-Risk Group: Baseline Visit & 2 Follow-up Annual Visits (w/ potential to have 3 additional visits in 1 year); Healthy Controls & RA Diagnosed: Baseline Visit & 1 Follow-up Visit, approximately 1 year later

    *Determine the role of sputum macrophage phagocytosis in NET clearance among At-Risk, healthy, & RA subjects

Sponsors and collaborators

Lead sponsor

University of Colorado, Denver

Other

Collaborators

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  • National Institutes of Health (NIH)

Registry information

Acronym: SPARO

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
Jul 16, 2020
Registry last updated
Jun 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.